February 15, 2023

February 15, 2023

Disparities According to Genetic Ancestry in the Use of Precision Oncology Assays

While not specifically about chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), these results offer some encouraging news regarding cancer care for adults with predominantly African ancestry in terms of their use of genomic testing to help inform their cancer treatments.

February 15, 2023

ASH 2022: Dr. Nirav Shah on Pirtobrutinib for Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor

Pirtobrutinib was generally well-tolerated, and most patients did not experience high-grade recurrence of the adverse event that led to discontinuation of the prior covalent Bruton tyrosine kinase inhibitor (BTKi). Pirtobrutinib may be an important option to extend the benefit of BTK inhibition among patients who could not tolerate previous

February 15, 2023

ASH 2022: Dr. James Blachly Discusses Results from a Phase 1/2 Dose Escalation and Expansion Study Evaluating MS-533, a Novel and Selective Protein Kinase C-Beta Inhibitor in Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

MS-553, a protein kinase C-beta (PKCß) inhibitor, is an exciting new agent in a yet-to-be-approved class of drugs that target an area of the B-cell receptor pathway independent of Bruton tyrosine kinase (BTK) and phospholipase C gamma 2 (PLCy2) mutations which confer resistance to BTK inhibitors.

February 15, 2023

Karen Jones on Warm Autoimmune Hemolytic Anemia and wAIHA Warriors

In this interview, Dr. Brian Koffman spoke with Karen Jones, executive director of wAIHA Warriors, a nonprofit dedicated to helping patients with warm autoimmune hemolytic anemia (wAIHA). They discussed wAIHA Warriors and how wAIHA is connected to chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

February 15, 2023

ASH 2022: Dr. Irina Murakhovskaya on Warm Autoimmune Hemolytic Anemia (wAIHA) in Patients with Chronic Lymphocytic Leukemia (CLL)

Warm autoimmune hemolytic anemia is a common and serious complication of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The ENERGY study will test the efficacy of nipocalimab for treating warm autoimmune hemolytic anemia.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

February 15, 2023

Disparities According to Genetic Ancestry in the Use of Precision Oncology Assays

ASH 2022: Dr. Nirav Shah on Pirtobrutinib for Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor

ASH 2022: Dr. James Blachly Discusses Results from a Phase 1/2 Dose Escalation and Expansion Study Evaluating MS-533, a Novel and Selective Protein Kinase C-Beta Inhibitor in Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Karen Jones on Warm Autoimmune Hemolytic Anemia and wAIHA Warriors

ASH 2022: Dr. Irina Murakhovskaya on Warm Autoimmune Hemolytic Anemia (wAIHA) in Patients with Chronic Lymphocytic Leukemia (CLL)

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT US

CONTACT